Fulcrum Therapeutics Inc

FULC remains in Stage 4 decline with a clear lower-high/lower-low sequence under declining EMAs and price confined below the 9EMA/21EMA region. A terminal Double Bottom suggests exhaustion, but without confirmed EMA repair or a higher high, bearish control persists. The recommended posture is to trim into any rally toward the overhead EMA zone. A sustained close and follow-through above the 21EMA would invalidate this bearish bias.

• ↑Phase 1B Pioneer trial: HbF from 7.1%→19.3% at week 12, reducing vaso-occlusive crises.
• ↑$333.3M cash on hand sustains trials and operations into 2029.
• ↓Q1 2026 net loss widened to $22.2M from $20.4M year-ago.